Antares Pharma Announces Partners Update of LibiGel[R] Safety Study.
Linked as:
Extract
Antares Pharma Announces Partners Update of LibiGel[R] Safety Study.
LibiGel uses Antares ATD(TM) Advanced Transdermal Delivery Gel System
EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex:AIS) partner BioSante Pharmaceuticals announced today that based upon a review of study conduct and blinded data from the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study, the LibiGel Safety Study External Executive Committee has recommended continuation of the LibiGel Phase...See the full content of this document
Sponsored links
